Vir Biotechnology to Present at 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Vir Biotechnology, a clinical-stage immunology company, announced that CEO George Scangos, Ph.D., will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on January 12th at 11:00 am PT/2:00 pm ET. The presentation will be accessible through a live webcast on the Vir website and will be archived for 30 days. Vir focuses on treating and preventing infectious diseases through innovative immunology technologies, with a pipeline targeting SARS-CoV-2, hepatitis B, influenza A, HIV, and tuberculosis.

SAN FRANCISCO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that George Scangos, Ph.D., chief executive officer will virtually present at the 39^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12^th at 11:00 am PT/ 2:00 pm ET.

A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there following the presentation for 30 days.

About Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting SARS-CoV-2, hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. For more information, please visit www.vir.bio.

FAQ

When is the J.P. Morgan Healthcare Conference presentation by Vir Biotechnology?

The presentation by Vir Biotechnology is scheduled for January 12th at 11:00 am PT/2:00 pm ET.

Where can I watch the Vir Biotechnology presentation?

You can watch the presentation live on the Vir website under Events & Presentations, and it will be archived there for 30 days.

Who is presenting for Vir Biotechnology at the conference?

George Scangos, Ph.D., the CEO of Vir Biotechnology, will be presenting at the conference.

What is the focus of Vir Biotechnology's current development pipeline?

Vir Biotechnology's current pipeline focuses on treatments for SARS-CoV-2, hepatitis B virus, influenza A, HIV, and tuberculosis.

What is the main goal of Vir Biotechnology?

Vir Biotechnology aims to treat and prevent serious infectious diseases through advanced immunology technologies.